Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AGX148 |
Trade Name | |
Synonyms | AGX 148|AGX-148 |
Drug Descriptions |
AGX148 are autologous patient-derived CD8-positive tumor infiltrating lymphocytes (TILs) that have been selected for the expression of CD103 and CD39, which potentially induce tumor cell death and decrease tumor growth (J Immunol (2022) 208 (1_Supplement): 117.06). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AGX148 | AGX148 | 0 | 0 |
AGX148 + Aldesleukin | AGX148 Aldesleukin | 0 | 1 |